Oncimmune Holdings has made several senior appointments including Professor Tariq Sethi as chief scientific officer.
Matthew Luttrell has also joined as chief commercial officer while Clea Rosenfeld is the listed firm’s new head of investor relations.
The Nottingham firm, a leading global immunodiagnostics group, is looking to commercialise products such as EarlyCDT Lung following the announcement of an €8.5 million credit facility.
EarlyCDT Lung is a CDT test that measures the levels of seven autoantibodies to tumour-associated antigens.
It claims to detect all types of lung cancer at all stages of disease with high accuracy.
Professor Sethi is a researcher, clinician and entrepreneur with over 35 years of combined academic and industry experience in the field of immunology, inflammation and lung cancer.
He will join Oncimmune next month.
Luttrell is a seasoned health and life science commercial executive with experience gained in large pharmaceutical companies across HIV, rare diseases, oncology and haematology.
Rosenfeld, a senior investor relations and corporate communications professional with over 15 years of experience working in FTSE 100 and 250 companies, joined the Oncimmune team in July.
“The appointments of Tariq, Matthew and Cléa add yet more expertise and depth to our leadership teams as we establish Oncimmune as a key player in supporting critical clinical decisions across the cancer care pathway,” said CEO Dr. Adam Hill.
“I’m delighted to welcome them and am pleased that Oncimmune’s potential attracts such high quality, experienced and seasoned professionals.”